Eli Lilly and Company $LLY Shares Sold by Candriam S.C.A.

Candriam S.C.A. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 417,282 shares of the company’s stock after selling 28,982 shares during the period. Eli Lilly and Company makes up about 2.0% of Candriam S.C.A.’s investment portfolio, making the stock its 7th largest position. Candriam S.C.A.’s holdings in Eli Lilly and Company were worth $383,803,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. increased its holdings in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $749,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 2.3%

Shares of NYSE LLY opened at $1,189.06 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The stock’s 50-day simple moving average is $1,098.66 and its 200-day simple moving average is $1,033.53. The firm has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.24, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the business posted $3.34 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.81 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on LLY shares. Guggenheim reiterated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Leerink Partners increased their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,263.41.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.